A new patent drug for arrhythmia——Shensong Yangxin capsules

[Functions and Indications]
To tonify qi, nourish yin, activate blood, unblock the collaterals, clear the heart and tranquilize the mind. Indicated for premature ventricular contraction of coronary heart disease due to deficiency of qi and yin and heart vessel stasis and obstruction, manifested as palpitations and restlessness, shortness of breath and lack of strength, aggravated upon exertion, oppressive pain in the chest, insomnia and dream disturbed sleep, night sweating, and lethargy.

[Main Ingredients]
Ginseng Radix et Rhizoma, Ophiopogonis Radix, Corni Fructus, Salviae Miltiorrhizae Radix et Rhizoma, Ziziphi Spinosae Semen (Stir-baked), Taxilli Herba, Paeoniae Radix Rubra, Eupolyphaga Steleophaga, Nardostachyos Radix et Rhizoma, Coptidis Rhizoma, Schisandrae Sphenantherae Fructus, Os Draconis.

[Dosage] Take orally, 2 to 4 capsules/time, 3 times/day, 4 weeks for a course of treatment.

[Specification] 0.4g/capsule.

[Packing] Blister package, 24 or 36 capsules/box, 400boxes/carton.

[MA Number] License of State Drug Administration Z20103032.

Application Research on Shensong Yangxin Capsule in the Treatment of Arrhythmia” won the Second Prize of National Science and Technology Progress Awards in 2009

● National Essential Drug List
● National Class- A Varieties for Medical Insurance Drugs
● National Key New Product designated by the Ministry of Science and Technology of the P.R.C.
● National Key New Product
● List of Community Health Medication designated by the Ministry of Health
● “11th-Five Year Plan” Special Project of National Major New Drug Development
● “12th-Five Year Plan” Special Project of National Major New Drug Development
● Major Project of Transferring Achievements of the Ministry of Industry and Information Technology of the P.R.C.

The only drug proved by evidence-based medicine to treat premature beat, paroxysmal atrial fibrillation and bradyarrhythmia safely and effectively
The only drug to treat arrhythmia and with integrated regulation of multi-ion and non-ionic channels
The only patent traditional Chinese medicine to treat arrhythmia and winning the Second Prize of National Science and Technology Progress Awards

Shensong Yangxin capsules——Integrated regulation and effect ion on both fast and slow diseases

Arrhythmia seriously threats human health and life. There was no new drug for the treatment of arrhythmia in western medicine over the past 20 years. Existing arrhythmia western medicines have the bigger side effect and may increase mortality even. Clinical evidence-based medicine research has confirmed that Shensong Yangxin Capsule can effectively treat premature beat and paroxysmal atrial fibrillation, improve slow ventricular rate, significantly relieve clinical symptoms such as palpitation, shortness of breath, and insomnia, and has no adverse cardiac reactions. It has been praised by the majority of doctors and patients, and become the leading brand for the treatment of arrhythmia in China.

With 1,476 cases included, the clinical evidence-based medicine research results confirmed that:

Participating Hospitals: 32 AAA hospitals led by Beijing Fuwai Hospital, Beijing Chaoyang Hospital and the First Affiliated Hospital of Nanjing Medical University

Fast-type diseases
● 859 cases of premature ventricular beat: The total effective rate of Shensong Yangxin was 65.8%, which was better than that of Mexiletine (50.7%)
● 349 cases of paroxysmal atrial fibrillation: Shensong Yangxin and Propafenone had the similar effect, 62.3% vs 58.6%
● Shensong Yangxin had better improvement of symptoms than Propafenone.

Regulate

Slow-type diseases
268 cases of slow-type bradyarrhythmia: The total effective rate of Shensong Yangxin was 63.5%, and the average ventricular rate was increased by 7.09 beats / min. The lower the ventricular rate, the more obvious the improvement.